Endocrinology

A pilot trial in 29 women suggests a combination of metformin and high dose fish oil could reduce triglycerides and ApoB-remnants among young women with polycystic ovary syndrome.

A study assessing levels of flourine in cosmetic products available in the US and Canada suggests many of these products could contain levels of chemicals that, over time, could cause harm.

A randomized trial comparing 3 dietary approaches, including 2 involving fasting, suggests the recently popularized approach does not provide any substantial benefits compared to a traditional diet.

A retrospective analysis of data from more than 30k patients with severe obesity suggests having a discussion about bariatric surgery with a clinician resulted in greater weight loss, regardless of if they underwent a bariatric procedure, but fewer than 9% had these discussions.

Data from the UK Biobank cohort details the increased risk of adverse health outcomes, including the development of diabetes and heart failure, among patients considered to have metabolically healthy obesity.

A comparison of women with PCOS to matched controls indicates women with PCOS were at a 26% greater risk of experiencing major adverse cardiovascular events than their counterparts without polycystic ovary syndrome.

A systematic review of clinical trials notes that topical eye drops may lead to favorable retinal and visual outcomes, despite heterogeneity across multiple studies.

Our latest case report from Dr. Brady Pregerson features a man in his 30s presenting to the ED after drinking and admits to forgetting his insulin and poor adherence to other antidiabetes medication. Can you determine the correct diagnosis?

An analysis of food frequency questionnaire and biomarker data from more than 7000 adults indicates consumption of 2 or more servings of whole fruit per day was associated with 36% lower odds of developing diabetes in the next half-decade.

The FDA has announced the approval of semaglutide 2.4 mg (Wegovy) for chronic weight management in patients with obesity or overweight—the first drug to receive such an approval from the FDA in more than half a decade.

The indication makes the Novo Nordisk product the first weekly injection GLP-1 agonist approved for managing overweight and obesity.

The EMDAC voted 10-7 to support the benefit-risks of teplizumab for delaying clinical type 1 diabetes.

The USPSTF has issued the organization's first recommendation on interventions for promoting healthy weight gain during pregnancy and also provided an overview of the evidence base used for the recommendation statement.

A 23-year study suggests presence of autoantibodies could aid clinicians in predicting the risk of developing type 1 diabetes among women with gestational diabetes.

A single-arm study examining the effects of a very-low calorie ketogenic diet over a 1-month period indicates the dietary approach was associated with improvements in body weight and sex hormones among men with overweight or obesity.

An analysis of WHI data indicates social isolation and loneliness were associated with significant increases in risk of major cardiovascular disease, even after adjustment for other clinical risk factors.

A retrospective review of ASCVD risk factors at baseline and 1 year after initiating hormone therapy among transgender adolescents suggests the increased risk of cardiovascular disease seen among this population could be driven by increased prevalence of baseline risk factors.

Pooled data from 10k women in the Lifetime Risk Pooling Project suggests premature menopause was associated with a 40% increase in risk of coronary heart disease.

A comparison of annual mortality rates related to cancer and cardiovascular disease is shedding light on the impact of the obesity epidemic on progress against both since 1999.

The SGLT-2 inhibitor drug class is expanding into treatment indications experts could not have predicted. Learn how DAPA-HF contributed to the understanding of dapagliflozin.

A new phase 1 trial presented at ECO 2021 demonstrates the impact of semaglutide on appetite and body weight in patients with obesity, indicating use of the GLP-1 RA reduced energy intake 35% and resulted in a nearly 10% reduction in body weight over 20 weeks.

Bayer has submitted a New Drug Application for the mineralocorticoid receptor antagonist.

Bigfoot Medical announced the FDA granted 510(k) clearance to the Bigfoot Unity System for use in patients with type 1 or type 2 diabetes aged 12 years and older.

Two studies examining RCTs of herbal and dietary supplements found none of these supplements provided a clinically meaningful reduction in body weight among patients with overweight or obesity.